Innoviva INVA 深 沪
已收盘 11-07 16:00:00 美东时间
20.86
+0.280
+1.36%
华盛通- 最 高21.095
- 今 开20.738
- 成交量 110.80万股
- 最 低 20.28
- 昨 收 20.58
- 总市值 13.09亿
- 52周最高 22.00
- 市盈率 静 57.61
- 换手率 0.00%
- 52周最低 16.52
- 委 比 -17.69%
- 总股本 6277.52万
- 历史最高 41.71
- 量 比 1.25
- 振 幅 3.96%
- 历史最低 6.36
- 每 手 1
- 风险率 1.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Cantor Fitzgerald Maintains Overweight on Innoviva, Raises Price Target to $31
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and raises the price target from $29 to $31.
11-06 22:42
Innoviva Q3 EPS $1.08 Beats $0.52 Estimate, Sales $107.800M Beat $91.309M Estimate
Innoviva (NASDAQ:INVA) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.52 by 109.71 percent. This is a 5300 percent increase over earnings of $0.02 per share from the same
11-06 05:47
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock
In the last three months, 5 analysts have published ratings on Innoviva (NASDAQ...
10-01 04:01
Goldman Sachs Initiates Coverage On Innoviva with Sell Rating, Announces Price Target of $17
Goldman Sachs analyst Asad Haider initiates coverage on Innoviva (NASDAQ:INVA) with a Sell rating and announces Price Target of $17.
09-30 21:06
生存恐怖游戏有哪些好玩 2024生存恐怖游戏排行榜前十
探寻2024年最令人胆寒的生存恐怖游戏盛宴！本文带你揭秘排行榜前十的刺激之作，从经典的逃生挑战到创新的技术革新，满足你对恐惧与紧张感的极致追求。无论是硬核玩家还...
08-27 11:14
A Look Ahead: Phibro Animal Health's Earnings Forecast
Phibro Animal Health (NASDAQ:PAHC) will release its quarterly earnings report o...
08-27 00:04
Congressional Trading Report: Rep. George Whitesides Sold Over $50K In Planet Labs Stock
Records from August 13, 2025 indicate that Representative George Whitesides of ...
08-14 23:00
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
During the last three months, 4 analysts shared their evaluations of Innoviva (...
08-12 02:01
